Sfoglia per Autore  CACCESE, MARIO

Opzioni
Mostrati risultati da 1 a 20 di 25
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series 2023 Padovan M.Cerretti G.Caccese M.Barbot M.Occhi G.Scaroni C.Lombardi G.Ceccato F. + EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM - -
Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study 2023 Caccese M.Bruno F.Cerretti G.Denaro L.Lombardi G. + JOURNAL OF NEURO-ONCOLOGY - -
Case report: The lesson from opioid withdrawal symptoms mimicking paraganglioma recurrence during opioid deprescribing in cancer pain 2023 Caccese, MarioCeccato, Filippo + FRONTIERS IN PAIN RESEARCH - -
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study 2023 Cerretti, GPadovan, MCaccese, MDenaro, LGuarneri, VLombardi, G + CLINICAL ONCOLOGY - -
Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients 2023 Giunco S.Cerretti G.Caccese M.De Rossi A. + ESMO OPEN - -
Valutazione dell'attività di pembrolizumab in pazienti con recidiva di glioma di alto-grado e perdita parziale o completa di espressione delle proteine del mismatch repair: studio monocentrico, osservazionale, prospettico 2022 CACCESE, MARIO - - -
The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation 2022 Tizianel, IreneCaccese, MarioTorresan, FrancescaLombardi, GiuseppeEvangelista, LauraCrimì, FilippoSepulcri, MatteoIacobone, MaurizioPadovan, MartaGaluppini, FrancescaZagonel, VittorinaScaroni, CarlaCeccato, Filippo CANCERS - -
Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care 2022 Ruggiero, ElenaTizianel, IreneCaccese, MarioLombardi, GiuseppePambuku, ArdiZagonel, VittorinaScaroni, CarlaCeccato, Filippo + CANCERS - -
PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction 2022 Spimpolo A.Berti S.Evangelista L.Causin F.Zorzi G.Caccese M.Padovan M.Zagonel V.Cecchin D. + BRITISH JOURNAL OF RADIOLOGY - -
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study 2022 Mario CacceseLuisa BelluFrancesco CavallinMatteo FassanVittorina ZagonelLombardi Giuseppe + CANCERS - -
Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification 2022 Cerretti, GiuliaCecchin, DiegoDenaro, LucaCaccese, MarioPadovan, MartaZagonel, VittorinaLombardi, Giuseppe ANTI-CANCER DRUGS - -
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib 2021 Santangelo A.Indraccolo S.Prandini P.DI Gennaro G.Caccese M.Zagonel V. + NEURO-ONCOLOGY - -
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 2021 Guarneri V.Zagonel V.Milella M.Cattelan A. M.Vianello A.Gori S.Aprile G.Oliani C.Bernardi D.Morandi P.Toso S.Di Liso E.Caccese M.Puccetti O.Celestino M.Dieci M. V.Conte P. + EUROPEAN JOURNAL OF CANCER - -
Phosphorylated acetyl-coa carboxylase is associated with clinical benefit with regorafenib in relapsed glioblastoma: REGOMA trial biomarker analysis 2020 Indraccolo S.Caccese M.Piga I.Pizzi M.Gardiman M. P.Zagonel V. + CLINICAL CANCER RESEARCH - -
Anaplastic Astrocytoma: State of the art and future directions 2020 Caccese M.Padovan M.D'Avella D.Gardiman M. P.Fassan M.Zagonel V. + CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY - -
Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study 2020 Parrozzani R.Midena E.Londei D.Padovan M.Marchione G.Caccese M.Midena G.Zagonel V.Frizziero L. + FRONTIERS IN ONCOLOGY - -
Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study 2020 Parrozzani, RaffaeleLombardi, GiuseppeMidena, EdoardoLeonardi, FrancescaLondei, DavidePadovan, MartaCaccese, MarioMarchione, GiuliaBini, SilviaZagonel, VittorinaFrizziero, Luisa THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY - -
Clinical management of diffuse low-grade gliomas 2020 Castellano A.Salvalaggio A.Cerretti G.Caccese M.Padovan M.Zagonel V. + CANCERS - -
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 2020 Lombardi, GiuseppeIndraccolo, StefanoFassan, MatteoMandruzzato, SusannaCaccese, MarioPizzi, MarcoPadovan, MartaMasetto, ElenaGardiman, Marina PaolaDenaro, LucaDei Tos, Angelo PaoloScarpa, AldoZagonel, Vittorina + CANCERS - -
Mismatch-repair protein expression in high-grade gliomas: A large retrospective multicenter study 2020 Caccese M.Fassan M.Cavallin F.Padovan M.Salvalaggio A.Gardiman M. P.Zagonel V. + INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES - -
Mostrati risultati da 1 a 20 di 25
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile